Emerging CAR-T Therapies in Large B-cell Lymphomas (LBCL): Highlights from ASH 2022 and Beyond

Experts discuss Large B-Cell Lymphoma (LBCL) and treatment strategies for patients with LBCL.

In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Experts provide their perspective on the treatment landscape for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).

Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting.

Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.